Healthcare AI spend grew 2.5x to $3.7 billion in 2026, and pharma discovery and research grew fastest, up 28.6x to $600 million, Menlo Ventures estimates in its 2026: The State of AI in Healthcare report, published on 16 November. Menlo’s survey behind it covers 550 U.S. healthcare executives, fielded by Morning Consult in September 2026.
The three fastest-growing categories in Menlo’s breakdown, clinical copilots ($550 million), patient engagement and front office ($450 million) and pharma discovery and research ($600 million), now total $1.6 billion. By our arithmetic that is more than ambient scribes ($950 million) and coding and billing ($600 million) combined, at $1.55 billion. A year earlier, on Menlo’s chart, the three were under $225 million together.
Business Pill · Distribution Advantage
An evergreen Business Engineer explainer on how reach decides which product gets tried. It teaches the general idea only and does not discuss Menlo’s report.
The key insight: As we read it, the new money in healthcare AI is going to work that sits further from the paperwork. By our arithmetic, the three fastest-growing categories on Menlo’s chart total $1.6 billion, against $1.55 billion for ambient scribes and coding and billing, the categories Menlo calls last year’s winners.
Where the $3.7 Billion Goes
Menlo’s category chart puts providers at $2,850 million, or 77% of the total, pharma at $700 million (19%) and payers at $150 million (4%). It says values are rounded to the nearest $25 million.
Its summary of the split: “Administrative AI still commands the biggest budgets, but clinical care and drug discovery are gaining ground”. Ambient scribes grew 1.6x and coding and billing 1.3x, against 5.5x for clinical copilots and 4.5x for patient engagement and front office.
Menlo calls healthcare the largest vertical AI market, “more than double the next-largest vertical, legal ($1.8B, +2.8x YoY)”. We first covered the $3.7 billion total from Menlo’s enterprise report in our 3 November piece on healthcare AI; the new report adds the category split.


What Was Posted on X
Posted by Menlo Ventures at 19:06 UTC on 16 November, this post announces the report and lists the five category figures with their growth multiples, from ambient scribes at $950 million (1.6x) to pharma discovery and research at $600 million (28.6x). The piece takes every figure from the report itself.
Drug Discovery: From Under $25 Million to $600 Million
Menlo’s chart puts 2025 spend on pharma discovery and research at under $25 million. It defines the $600 million as “pharma external spend on AI in drug discovery, including models, platforms, harnesses, and data (but excluding assets)”. All pharma AI spend rose from $30 million to $700 million, or 23x, by Menlo’s count.
The report says 43% of life sciences companies now run AI at scale, up from 12% in 2025, led by pharma at 51%. It says Chai Discovery signed seven top drugmakers in 2026, and that “Anthropic’s S-1 shows nine of the top 10 pharma companies are current customers”.
Menlo’s survey also measures expectations: 84% of R&D leaders expect AI to cut at least a year from new programs over the next three to five years, while “93% expect first approval of AI-discovered drugs within five years but only 28% within two years”.
Scribes: Incumbents Took 68% of New Dollars
In scribing, Menlo says incumbent add-ons led by Microsoft Dragon Copilot and Epic’s Art “won 68% of new scribe dollars this year and grew 120%, while AI-native scribes grew 28% but lost 13% market share”. Incumbents now hold 46% of a $950 million scribe market, it says.
Buying has slowed too. Menlo says average time from first meeting to closed deal rose from seven to 10 months for health systems and from five to 11 months for outpatient providers between 2025 and 2026.
Closer to the Patient
In clinical copilots, Menlo says OpenEvidence commands “an estimated 64% of revenue, more than 6x the next vendor”. OpenEvidence is also the partner in Apple’s health study, as our piece on Apple’s AI health study reported.
Menlo’s survey finds providers still prefer to buy chart review (75%) and coding and billing (71%) from their EHR, but 55% prefer prior authorization and 51% prefer patient navigation from a third party. Recent funding in the field is in our tally of health AI rounds.
Related: health AI startup August, which works in patient engagement and front office, raised $12 million from Accel and Peak XV on Monday for an agent that calls doctors’ offices, as our piece on August’s $12 million round reports.
Payers spent $150 million, about 4% of the market, and Menlo says 43% of payers report that provider documentation and coding AI raised their medical cost trend in 2026, up from 23% in 2025.
The Structural Read
As we read Menlo’s scribe figures, the category that started the cycle is now a distribution contest: incumbents took 68% of new scribe dollars, by Menlo’s estimate.
As we read the drug discovery numbers, the 28.6x multiple measures a market that barely existed in 2025 on Menlo’s chart, so the $600 million level matters more than the multiple.
Menlo Ventures, 2026: The State of AI in Healthcare
“AI agents are now unlocking these jobs that traditionally had been dominated by human labor rather than software”
Three Implications
FOR AI-NATIVE SCRIBE COMPANIES Menlo says incumbent add-ons won 68% of new scribe dollars and AI-native scribes lost 13% market share.
FOR DRUG DISCOVERY AI Menlo puts pharma discovery and research at $600 million, up 28.6x, and says 43% of life sciences companies now run AI at scale.
FOR PAYERS Menlo puts payer AI spend at $150 million and says 43% of payers report that provider coding AI raised their medical cost trend.
The Business Engineer Lens
This story maps onto the Business Engineer framework From SaaS to AGaaS.
The framework puts the shift in one sentence: “SaaS is charged for access to tools. AGaaS charges for the execution of outcomes.”
As we read Menlo’s report, its line that AI agents are unlocking jobs once dominated by human labor rather than software is that shift applied to healthcare; the framework does not discuss Menlo’s report.
What Is Not Established
The dollar figures are Menlo’s estimates, rounded on its chart to the nearest $25 million, so the 28.6x multiple rests on a 2025 base Menlo shows only as under $25 million. Our $1.6 billion and $1.55 billion totals add Menlo’s rounded category figures.
Menlo’s survey of 550 executives splits into 150 provider technology decision-makers, 100 health plan executives and 300 pharma and biotech executives. Menlo Ventures is an investor in companies the report names, including Anthropic, OpenEvidence and Chai Discovery. We did not contact Menlo for this piece.
The Bottom Line
Menlo Ventures estimates healthcare AI spend at $3.7 billion in 2026, with pharma discovery and research up 28.6x to $600 million. By our arithmetic, clinical copilots, patient engagement and drug discovery now total $1.6 billion, against $1.55 billion for ambient scribes and coding and billing, where Menlo says incumbents took 68% of new scribe dollars.
95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.
A note on sourcing. We read Menlo Ventures’ report page in full, including its Data Sources and Methodology section and its category chart, and Menlo’s post on X announcing it. The dollar figures are Menlo’s estimates; the totals of $1.6 billion and $1.55 billion and the under-$225 million 2025 figure are our arithmetic from Menlo’s rounded category values. Menlo Ventures is an investor in Anthropic, OpenEvidence and Chai Discovery, among companies the report names. We did not contact Menlo for this piece.
Sources: Menlo Ventures: 2026: The State of AI in Healthcare (16 Nov 2026) · Menlo Ventures on X (16 Nov 2026)









